stella
beta
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients — Stella
Home
/
NSCLC, Stage III
/
View on ClinicalTrials.gov
Recruiting
Back to NSCLC, Stage III trials
Trial locations
(2 sites)
United States
The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Rhode Island Hospital, Brown University, Providence, Rhode Island